Epilepsy Drug GuideFDA Approves New Use for Seizure Drug Lamictal®Landover, MD, September 29, 2006 - Earlier this week, the Food and Drug Administration approved the use of lamotrigine, or Lamictal®, (manufactured by GlaxoSmithKline) as an adjunctive therapy for children (2-20 years) and adults who experience grand mal seizures, also known as primary generalized tonic-clonic (PGTC) seizures. Approximately 20 percent of people with epilepsy experience these types of seizures, which are more common in children than in adults.VNS Therapy has been proven in clinical studies to provide a safe and effective way to control seizures for many patients. For many, the results include improved, for many , is an improvement in alertness and memory as well as plus more energy and a better disposition. Because mood. And because it is not a drug, the VNS has allowed many people to reduce the number or dosage of medications they take. The VNS does not typically cause side effects like depression, confusion, weight gain, fatigue, insomnia, or low energy. The most common side effects include hoarseness, a prickling feeling on the skin, shortness of breath and increased coughing. Some of these side effects diminish over time. With any surgery, there is a risk of infection.
|